Comparison between 10 days dual therapy and 14 days dual therapy for frist-line Helicobacter pylori eradication: a randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017543

Enrollment

Unknown

Registered

2018-08-03

Start date

2018-07-25

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diseases of upper digestive tract

Interventions

Group A:10 days dual therapy

Group B:14 days dual therapy

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years old, male or female; 2. Gastroscopy diagnosis of chronic gastritis,with or without gastric ulcer or duodenal ulcer healed; 3. The rapid urease test or the urea breath test was positive; 4. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. have taken PPIs, H2RAS, antibiotics,bismuth or probiotics in the last 4 weeks; 2. patients with pregnancy,nursing or fertility programs during the study period; 3. taking NSAIDs,adrenal cortical hormone,anticoagulants or alcohol; 4. history of hypersensitivity to study drugs; 5. serious concomitant diseases:heart,lung,liver,kidney,metabolic disease,mental illness or malignant tumors; 6. previous gastric or esophagus surgeries; 7. have participated in other drug research in the last 3 months; 8. difficult to complete follow-up or have other factors that may affect compliance.

Design outcomes

Primary

Measure	Time frame
eradication rate;	—

Secondary

Measure	Time frame
CYP2C19 genotype;Compliance;cost-efficacy ratio;	—

Countries

China

Contacts

Public ContactChunhui LAN

Daping Hospital, Army Medical University

lanchunhui@dphospital.tmmu.edu.cn+86 13896067955

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026